Beta-secretase Inhibitor

BACE1-IN-11 is a BACE1 inhibitor. BACE1-IN-11 has the BACE1 inhibitory activity with an IC₅₀ value of 72 μM. BACE1-IN-11 can be used for the research of Alzheimer’s disease (AD) .

TB-9, a Tasiamide B (HY-N15154) derivative, is a potent cathepsin D, cathepsin E, and BACE1 inhibitor with IC₅₀s of 0.0783 nM, 0.724 nM, and 54.2 nM, respectively.

GRL-8234 is a potent β-secretase (BACE1) inhibitor with blood-brain barrier penetration (K_i = 1.8 nM). GRL-8234 can rescue age-related cognitive decline in Tg2576 mice. GRL-8234 can be used in the research related to Alzheimer's disease (AD).

BACE2 Human Pre-designed siRNA Set A contains three designed siRNAs for BACE2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Eslicarbazepine acetate (Standard) is the analytical standard of Eslicarbazepine acetate. This product is intended for research and analytical applications. Eslicarbazepine acetate (BIA 2-093), an antiepileptic agent, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel.

AChE-IN-63 (Compound 5AD) is a selective inhibitor of hAChE (IC₅₀=0.103 μM). AChE-IN-63 also inhibits hBChE and hBACE-1 (IC₅₀= 10 μM (hBChE); 1.342 μM (hBACE-1)). AChE-IN-63 inhibits Aβ aggregation, preventing the formation and deposition of Aβ1-42. AChE-IN-63 can effectively penetrate the blood-brain barrier and is orally effective. It is primarily used in Alzheimer's disease research.

2-Acetoxyacorenone (compound 8) is a sesquiterpenoid, which can be isolated from the rhizome of Acorus tatarinowii. 2-Acetoxyacorenone has potent AChE and β-BACE1 inhibitory activity and can be used in the study of Alzheimer's disease.

TAK-070 Free base is a noncompetitive and orally active BACE1 inhibitor (IC₅₀: 3.15 μM). TAK-070 Free base can be used for research of Alzheimer’s disease (AD). TAK-070 Free base inhibits brain levels of soluble Aβ, and improves cognitive impairments in AD model.

BACE1-IN-12 (compound 7g) is a potent and BBB-penetrated BACE1 inhibitor, with an IC₅₀ of 8.9 µM. BACE1-IN-12 shows selective BuChE (butyrylcholinesterase) inhibitory activity with an IC₅₀ of 3.2 µM. BACE1-IN-12 shows effective antioxidant effect with an IC₅₀ of 10.2 μM (DPPH). BACE1-IN-12 might be served as a potential anti-Alzheimer agent.

β-Secretase Inhibitor III is an extremely selective BACE1 inhibitor (K_i = 0.13 nM).

SSZ is a multi-target inhibitor, which targets multiple pathological mechanisms of Alzheimer's disease (AD). SSZ targets acetylcholinesterase, butyrylcholinesterase, β-site amyloid precursor protein cleavage enzyme 1 (BACE1), and γ-secretase. SSZ ameliorates Alzheimer’s diseases and exhibits neuroprotective effect in mice.

Bace1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bace1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

OM99-2, an eight residue peptidomimetic, tight-binding inhibitor of human brain memapsin 2 with a K_i value of 9.58 nM. OM99-2 is significantly advanced the development of BACE1 inhibitor. OM99-2 has the potential for the research of the Alzheimer's disease.

LY-2434074 is a selective β-secretase (BACE) inhibitor with an IC₅₀ <100 nM. LY-2434074 can inhibit amyloid-β (Aβ₄₀ and Aβ₄₂) production. LY-2434074 can be used for the research of neurological disease, such as Alzheimer's disease.

β-Secretase Inhibitor II is a β-Secretase inhibitor. β-Secretase Inhibitor II is a simple tripeptide aldehyde (IC₅₀=700 nM for inhibition of total Aβ and IC₅₀=2.5 μM for Aβ_1–42). β-Secretase Inhibitor II can be used for the research of Alzheimer's disease.

AChE-IN-82 (compound 49) is an acetylcholinesterase (AChE) inhibitor. AChE-IN-82 inhibits eeAChE, eqBChE, hMAO-A, hMAO-B, and BACE-1 with IC₅₀s of 0.072, 9.81, 14.52, 0.024, 2.42 μM, respectively. AChE-IN-82 inhibits COX-1, COX-2 and 5-LOX with IC₅₀s of 60.41, 0.187, 0.18 μM, respectively. AChE-IN-82 shows an excellent neuroprotective effect by significantly reducing oxidative stress induced by H₂ O₂.

BACE1-IN-9 (compound 82b) is a potent BACE1 (β-site APP cleaving enzyme 1) inhibitor, with an IC₅₀ of 1.2 µM.

hAChE/hBACE-1-IN-2 is a potent, orally active, blood-brain barrier transboundary triple inhibitor of hAChE, hBChE, and HACE-1 with IC₅₀s of 0.113 μM, 1.48 μM and 0.38 μM, respectively. hAChE/hBACE-1-IN-2 has antioxidant activity. hAChE/hBACE-1-IN-2 also inhibits Aβ1_1-42 aggregation. hAChE/hBACE-1-IN-2 can be used to study Alzheimer's disease.

Eslicarbazepine-d₄ (BIA 2-194-d₄) is deuterium labeled Eslicarbazepine. Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.

Tenuifolin (Standard) is the analytical standard of Tenuifolin. This product is intended for research and analytical applications. Tenuifolin is effective and has a protective action. Tenuifolin inhibits β-secretase decreases Aβ protein secretion, suppresses Aβ25-35 secretion, and subsequently caspase-3 and caspase-9 become active. Tenuifolin's ability to lower AChE activity, increase at the same time, increase the ability of the upper glands, and improve the ability to read and remember. Research on tenuifolin's potential for use in urinary disease (AD).